803 related articles for article (PubMed ID: 23818246)
21. PTPROt maintains T cell immunity in the microenvironment of hepatocellular carcinoma.
Hou J; Deng L; Zhuo H; Lin Z; Chen Y; Jiang R; Chen D; Zhang X; Huang X; Sun B
J Mol Cell Biol; 2015 Aug; 7(4):338-50. PubMed ID: 26117839
[TBL] [Abstract][Full Text] [Related]
22. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
[TBL] [Abstract][Full Text] [Related]
23. Targeting tumor-infiltrating Ly6G
Chang CJ; Yang YH; Chiu CJ; Lu LC; Liao CC; Liang CW; Hsu CH; Cheng AL
Int J Cancer; 2018 May; 142(9):1878-1889. PubMed ID: 29266245
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
Lozano T; Villanueva L; Durántez M; Gorraiz M; Ruiz M; Belsúe V; Riezu-Boj JI; Hervás-Stubbs S; Oyarzábal J; Bandukwala H; Lourenço AR; Coffer PJ; Sarobe P; Prieto J; Casares N; Lasarte JJ
J Immunol; 2015 Oct; 195(7):3180-9. PubMed ID: 26324768
[TBL] [Abstract][Full Text] [Related]
25. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
Fernando J; Malfettone A; Cepeda EB; Vilarrasa-Blasi R; Bertran E; Raimondi G; Fabra À; Alvarez-Barrientos A; Fernández-Salguero P; Fernández-Rodríguez CM; Giannelli G; Sancho P; Fabregat I
Int J Cancer; 2015 Feb; 136(4):E161-72. PubMed ID: 25053293
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
Zahavi T; Lanton T; Divon MS; Salmon A; Peretz T; Galun E; Axelrod JH; Sonnenblick A
Oncotarget; 2016 Jan; 7(4):4860-70. PubMed ID: 26695439
[TBL] [Abstract][Full Text] [Related]
27. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
Zhang QB; Sun HC; Zhang KZ; Jia QA; Bu Y; Wang M; Chai ZT; Zhang QB; Wang WQ; Kong LQ; Zhu XD; Lu L; Wu WZ; Wang L; Tang ZY
PLoS One; 2013; 8(2):e55945. PubMed ID: 23409093
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
Desar IM; Jacobs JH; Hulsbergen-vandeKaa CA; Oyen WJ; Mulders PF; van der Graaf WT; Adema GJ; van Herpen CM; de Vries IJ
Int J Cancer; 2011 Jul; 129(2):507-12. PubMed ID: 20839259
[TBL] [Abstract][Full Text] [Related]
31. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
Zhang SS; Ni YH; Zhao CR; Qiao Z; Yu HX; Wang LY; Sun JY; Du C; Zhang JH; Dong LY; Wang K; Gao JJ
Acta Pharmacol Sin; 2018 Mar; 39(3):438-448. PubMed ID: 29188798
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
Nojiri K; Sugimoto K; Shiraki K; Tameda M; Inagaki Y; Ogura S; Kasai C; Kusagawa S; Yoneda M; Yamamoto N; Takei Y; Nobori T; Ito M
Int J Oncol; 2013 Jan; 42(1):101-8. PubMed ID: 23123700
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
34. A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
Song JS; Chang CC; Wu CH; Dinh TK; Jan JJ; Huang KW; Chou MC; Shiue TY; Yeh KC; Ke YY; Yeh TK; Ta YN; Lee CJ; Huang JK; Sung YC; Shia KS; Chen Y
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753481
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib inhibition of hepatic stellate cell proliferation in tumor microenvironment of hepatocellular carcinoma: a study of the sorafenib mechanisms.
Geng ZM; Jha RK; Li B; Chen C; Li WZ; Zheng JB; Wang L; Huanchen S
Cell Biochem Biophys; 2014 Jul; 69(3):717-24. PubMed ID: 24633454
[TBL] [Abstract][Full Text] [Related]
36. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
[TBL] [Abstract][Full Text] [Related]
38. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Ho V; Lim TS; Lee J; Steinberg J; Szmyd R; Tham M; Yaligar J; Kaldis P; Abastado JP; Chew V
Oncotarget; 2015 Sep; 6(29):27252-66. PubMed ID: 26287667
[TBL] [Abstract][Full Text] [Related]
39. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]